DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.

BACKGROUND Nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR)-B, peroxisome proliferator-activated receptor gamma, and retinoic acid receptor alpha, have been implicated in breast cancer etiology and progression. We investigated the role of dendritic cell-specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast cancer. METHODS The effect of DC-SCRIPT on the transcriptional activity of nuclear receptors was assessed by luciferase reporter assays. DC-SCRIPT expression in normal and tumor tissue from breast cancer patients was analyzed by polymerase chain reaction and immunohistochemistry. The prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group. Univariate and multivariable Cox proportional hazards model analyses were performed. All statistical tests were two-sided. RESULTS DC-SCRIPT suppressed ER- and PR-mediated transcription in a ligand-dependent fashion, whereas it enhanced the retinoic acid receptor alpha- and peroxisome proliferator-activated receptor gamma-mediated transcription. In breast tissue samples from nine patients, DC-SCRIPT mRNA was expressed at lower levels in the tumor than in the corresponding normal tissue (P = .010). Patients in the discovery group with high tumor DC-SCRIPT mRNA levels (66%) had a longer disease-free interval than those with a low DC-SCRIPT mRNA level (34%) (hazard ratio [HR] of recurrence for high vs low DC-SCRIPT level = 0.23, 95% confidence interval [CI] = 0.06 to 0.93, P = .039), which was confirmed in the validation group (HR of recurrence = 0.50, 95% CI = 0.26 to 0.95, P = .034). This prognostic value was confined to patients with ER- and/or PR-positive tumors (discovery group: HR of recurrence = 0.16, 95% CI = 0.03 to 0.89, P = .030; validation group: HR of recurrence = 0.42, 95% CI = 0.19 to 0.91, P = .028) and was also observed in the second validation group (HR = 0.46, 95% CI = 0.22 to 0.97, P = .040). DC-SCRIPT was an independent prognostic factor after correction for tumor size, lymph node status, and adjuvant therapy (n = 145; HR = 0.50, 95% CI = 0.29 to 0.85, P = .010). CONCLUSION DC-SCRIPT is a key regulator of nuclear receptor activity that has prognostic value in breast cancer.

[1]  S. Fuqua,et al.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. , 2009, The American journal of pathology.

[2]  K. White,et al.  Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast Cancer , 2009, Cell.

[3]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[4]  S. Conzen.  Minireview: nuclear receptors and breast cancer. , 2008, Molecular endocrinology.

[5]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[6]  I. Ellis,et al.  The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome , 2008, Breast Cancer Research and Treatment.

[7]  A. Hart,et al.  PRAME expression and clinical outcome of breast cancer , 2008, British Journal of Cancer.

[8]  N. Turner,et al.  Management of breast cancer—Part II , 2008, BMJ : British Medical Journal.

[9]  N. Turner,et al.  Management of breast cancer—Part I , 2008, BMJ : British Medical Journal.

[10]  T. Schug,et al.  Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR , 2008, Proceedings of the National Academy of Sciences.

[11]  Y. Wan,et al.  Nuclear Receptors and Inflammatory Diseases , 2008, Experimental biology and medicine.

[12]  R. Lanz,et al.  Nuclear receptor coregulators and human disease. , 2008, Endocrine reviews.

[13]  Liming Pei,et al.  Nuclear receptors: Decoding metabolic disease , 2008, FEBS letters.

[14]  John H. White,et al.  Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells , 2007, Nucleic acids research.

[15]  B. O’Malley,et al.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. , 2007, Molecular cell.

[16]  B. O’Malley.  Coregulators: from whence came these "master genes". , 2007, Molecular endocrinology.

[17]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[18]  J. Massagué.  Sorting out breast-cancer gene signatures. , 2007, The New England journal of medicine.

[19]  Simak Ali,et al.  ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases , 2006, Nucleic acids research.

[20]  K. Horwitz,et al.  Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. , 2006, Molecular endocrinology.

[21]  H. Gronemeyer,et al.  Twenty years of nuclear receptors , 2006, EMBO reports.

[22]  Yi Zhang,et al.  Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Looman,et al.  Molecular characterization of the murine homologue of the DC‐derived protein DC‐SCRIPT , 2006, Journal of leukocyte biology.

[24]  J. Foekens,et al.  Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Yager,et al.  Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.

[26]  M. Looman,et al.  Identification and Characterization of DC-SCRIPT, a Novel Dendritic Cell-Expressed Member of the Zinc Finger Family of Transcriptional Regulators1 , 2006, The Journal of Immunology.

[27]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Papadaki,et al.  PPARγ expression in breast cancer: clinical value and correlation with ERβ , 2005, Histopathology.

[30]  P. Span,et al.  Survivin is an independent prognostic marker for risk stratification of breast cancer patients. , 2004, Clinical chemistry.

[31]  D. Hayes.  Markers of increased risk for failure of adjuvant therapies. , 2003, Breast.

[32]  E. Dmitrovsky,et al.  Retinoids in cancer therapy and chemoprevention: promise meets resistance , 2003, Oncogene.

[33]  I. Bièche,et al.  Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[35]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[36]  M. Hung,et al.  Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells , 2002, Oncogene.

[37]  C. Meijer,et al.  Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[40]  John Calvin Reed,et al.  Interaction of BAG-1 with Retinoic Acid Receptor and Its Inhibition of Retinoic Acid-induced Apoptosis in Cancer Cells* , 1998, The Journal of Biological Chemistry.

[41]  B. Spiegelman,et al.  ADD1/SREBP1 activates PPARγ through the production of endogenous ligand , 1998 .

[42]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[43]  Qun Zhou,et al.  Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro , 1997, Oncogene.

[44]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[45]  V. Laudet,et al.  Evolution of the nuclear receptor gene superfamily. , 1992, The EMBO journal.

[46]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[47]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[48]  Y. Chung,et al.  Regulatory elements mediating transcription from the Drosophila melanogaster actin 5C proximal promoter , 1990, Molecular and cellular biology.

[49]  H. Ponta,et al.  The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. , 1987, The EMBO journal.

[50]  M. Beato,et al.  The hormone regulatory element of mouse mammary tumour virus mediates progesterone induction. , 1986, The EMBO journal.

[51]  Keller Jh,et al.  Management of breast cancer. , 1970 .

[52]  E. Roberts,et al.  Management of breast cancer , 1967, BMJ.

[53]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[54]  F. Massey.  The Kolmogorov-Smirnov Test for Goodness of Fit , 1951 .

[55]  Ton Feuth,et al.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes , 2005, Laboratory Investigation.

[56]  G. Chinnadurai.  CtBP family proteins: more than transcriptional corepressors. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[57]  S. Hilsenbeck,et al.  Role of the Estrogen Receptor Coactivator AIB 1 ( SRC-3 ) and HER-2 / neu in Tamoxifen Resistance in Breast Cancer , 2003 .

[58]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[59]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[60]  B. Spiegelman,et al.  ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. , 1998, Proceedings of the National Academy of Sciences of the United States of America.